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Summary
Cancer cell migration is a required step in cancer me-
tastasis. We screened for inhibitors of cancer cell mi-
gration of microbial origin, and obtained moverastin,
a member of the cylindrol family, from Aspergillus
sp. F7720. However, the results of an NMR spectro-
scopic analysis raised the possibility that moverastin
is a mixture of two diastereomers. Separation of the
C-10 epimers of synthetic moverastin and a bioassay
revealed that both diastereomers (moverastins A and
B) had inhibitory effects on cell migration. Further-
more, we demonstrated that moverastins A and B in-
hibited FTase in vitro, and they also inhibited both
the membrane localization of H-Ras and the activation
of the PI3K/Akt pathway in EC17 cells. Thus, moveras-
tins inhibited the migration of tumor cells by inhibiting
the farnesylation of H-Ras, and subsequent H-Ras-
dependent activation of the PI3K/Akt pathway.
Introduction
Cell migration is a central feature of a range of physio-
logical processes, including embryonic development,
tissue repair, and inflammation. Cell migration is a com-
plex, multistep process that involves protrusion of the
leading edge of the cell, the formation of adhesion com-
plexes, myosin/actin-mediated cell contraction, and the
release of adhesion complexes at the cell’s rear. When
cells migrate, filopodia and lamellipodia are formed at
the leading edge. Filopodia and lamellipodia are made
up of actin filaments, and are formed mainly through ac-
tin polymerization [1–4]. Consistent with the complexity
of the cell migration process, a variety of intracellular
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pathways have been identified in the regulation of this
process. The Rho family of small GTPase proteins, in-
cluding Rho, Rac, and Cdc42, modulates cell migration
by affecting the dynamic reorganization of the actin cy-
toskeleton [5, 6]. Rho regulates the formation of contrac-
tile actin-myosin filaments to form stress fibers, while
Rac and Cdc42 regulate the formation of lamellipodia
and filopodia, respectively [7–9].
Another small GTPase protein, Ras, is also known to
make an essential contribution to cell migration in endo-
thelial and fibroblast cells [8, 10–12]. Three members of
the Ras family, H-, K-, and N-Ras, are ubiquitously ex-
pressed in mammalian cells. Among Ras proteins, the
amino-terminal 85 amino acids are identical, and the mid-
dle 80 amino acids exhibit 85% homology, while the
carboxy-terminal sequences are highly divergent [13].
The biological effects of Ras proteins are exerted
through the activation of several downstream effectors.
Ras stimulates the serine/threonine kinase Raf, leading
to the activation of the downstream kinase mitogen-
activated protein kinase (MAPK)/extracellular signal-
regulated kinase (Erk) kinase (MEK), which, in turn,
phosphorylates Erks/MAPK. Activated Erks/MAPK phos-
phorylates, and thereby enhances the activity of myosin
light chain kinase, resulting in the phosphorylation of my-
osin light chains and cell migration [14, 15]. Moreover,
activated Erks/MAPK accumulates in the nucleus and
phosphorylates Elk-1, which results in the expression of
several genes, such as matrix metalloprotease (mmp)-9;
MMP-9 activity is required for the induction of cell motil-
ity [16]. In addition to the Raf/MEK/Erk pathway, a phos-
phoinositide 3-OH kinase (PI3K)/Akt pathway is shown
to be critical for the mitogenic and oncogenic effect of
Ras. PI3K interacts with Ras and is activated as a result
[17–19]. One target of PI3K is serine/threonine kinase
Akt. Akt may be regulated by both phosphorylation and
by the direct binding of PI3K lipid products to the Akt
pleckstrin homology (PH) domain. The PI3K/Akt path-
way has been implicated in the regulation of the actin cy-
tosleleton, and is necessary for Cdc42- and Rac-induced
cell motility and invasiveness [20].
The Rho family and the Ras family of small GTPases
are all modified posttranslationally at their carboxy-ter-
mini by isoprenoid lipids. This prenylation through the
thiol group of a cysteine side chain near the carboxylate
terminus affects the attachment of the GTPase to the
plasma membrane, which is crucial to its activation
[21]. The isoprenyl substrate for these reactions is either
farnesyl pyrophosphate (FPP) or geranylgeranyl pyro-
phosphate (GGPP), which are derived from mevalonate.
Enzymes that catalyze protein prenylation are farnesyl-
transferase (FTase) and geranylgeranyltransferase
(GGTase). FTase catalyzes the farnesylation of proteins
with a carboxy-terminal CAAX motif, where C is cyste-
ine, A is an aliphatic amino acid, and X is methionine,
serine, glutamine, alanine, or cysteine. Like FTase,
GGTase catalyzes the geranylgeranylation of proteins
terminating with a CAAX motif, where X is restricted to
leucine, isoleucine, or phenylalanine. Among small
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their activation. On the other hand, Rho A, Rac, and
Cdc42 require geranylgeranylation. Inhibitors of these
prenyltransferases, which inhibit the translocation to
the plasma membrane and the function of these small
GTPase proteins, affect the cytoskeleton and inhibit
cell migration [22, 23].
In addition to physiological conditions, cell migration
is also involved in pathological conditions, such as me-
tastasis [24, 25]. In metastasis, tumor cells migrate from
the initial tumor mass into the circulatory system, which
they subsequently leave, migrate into a new site, invade
into a tissue compartment, and grow. Thus, the migra-
tion of tumor cells is essential for invasion of the extra-
cellular matrix and for cell dissemination. Inhibition of
the cell migration involved in the invasion process repre-
sents a potential therapeutic approach to the treatment
of tumor metastasis. Therefore, we have screened for
compounds which inhibit the migration of tumor cells
to develop a new antimetastatic drug of microbial origin.
In this study, we have obtained moverastin from the cul-
ture broth of Aspergillus sp. F7720, as a mixture of two
diastereomers at the C-10 secondary allylic alcohol.
Chemical synthesis and bioassays revealed that both
of the C-10 epimers (moverastins A and B) had inhibitory
effects on cell migration. Our data suggest that mover-
astins A and B inhibited the farnesylation of H-Ras,
thereby suppressing cell migration in human esopha-
geal tumor cells.
Results
Preparation of the Cell Migration Inhibitor
Moverastin from Aspergillus sp. F7720
We screened more than 2000 microbial extracts for in-
hibitors of tumor cell migration by conducting wound
healing assays using human esophageal carcinoma
EC17 cells, and found activity in the culture broth of
a solid-isolated fungal strain, F7720. Since taxonomic
studies revealed strain F7720 to belong to Aspergillus
or a related genus, we named the strain Aspergillus sp.
F7720. The strain has been deposited in the National In-
stitute of Advanced Industrial Science and Technology,
Tsukuba, Japan (Accession No. FERM P-18198). The
culture broth (1 liter) was filtered to be separated into
a supernatant and a mycelial cake. The supernatant
was extracted with EtOAc (1 liter), and evaporated to
give a yellow oil (1.52 g). The yellow oil was loaded on
a silica gel column, which was eluted with CHCl3-
MeOH (100:1). The eluate was concentrated in vacuo,
and the yellow powder (37.6 mg) obtained was dissolved
in MeOH and was applied to a Sephadex LH-20 column
and eluted with MeOH. The active fraction (28.7 mg) was
chromatographed on preparative silica gel thin-layer
plates (Kieselgel 60F254; Merck Co., Darmstadt, Ger-
many) using a toluene-acetone (2:1) system. An active
band (9.7 mg) thus obtained was further purified by
HPLC (Capcell Pak C18 column, 2.0 3 25 cm) with
55% aq acetonitrile to yield moverastin (Figure 1A) as
a colorless powder (1.8 mg).
Structural Determination of Moverastin
Moverastin gave an (M + H)+ ion peak at m/z 389.2307 in
the HRFAB-MS analysis, and its molecular formula wasestablished as C23H32O5 (calculated for 389.2328). In the
13C NMR spectrum of moverastin in CDCl3, some of the
signals were observed as two peaks (peak height ratio
was approximately 2:1). Considering this observation
and the result of HRFAB-MS, moverastin was proposed
to be a mixture of two diastereomers (Figure 1A). Since
the yield of moverastin was low, and the separation of
the diastereomers was difficult, the structure of each di-
astereomer was analyzed in the mixture. We named the
major component moverastin A (1) and the minor com-
ponent moverastin B (2).
The 13C NMR spectrum of moverastin A displayed 23
carbons. The C-H COSY spectrum of moverastin A re-
vealed the presence of the following types of carbon:
four methyls, five sp3 methylenes, one exomethylene,
three sp3 methines (one of which was oxygenated),
one sp2 methine, one sp3 quaternary carbon, six sp2
quaternary carbons, and two carbonyl carbons (alde-
hyde and ketone). The 1H and 13C chemical shifts of
moverastin A are listed in Table 1.
Analysis of the 1H-1H DQF COSY spectrum of mover-
astin A gave four partial fragments, as shown by bold
lines (Figure 1B), the structural fragments C9 (d28.53)-
C10 (d76.60), C12 (d24.87)-C13 (d35.56), C21 (d14.96)-
C15 (d36.13)-C16 (d30.92)-C17 (d41.54), and C19
(d50.41)-C22 (d7.57).
The HMBC experiment was used to assemble these
fragments into moverastin A. 1H-13C long-range correla-
tions from H-8 (d10.05, aldehyde) to C-1 (d112.85) and
C-6 (d164.06), and from H-7 (d2.50) to C-1, C-2
(d142.65), and C-3 (d111.98) were observed in the
HMBC spectrum. In addition, correlations from H-9
(d2.89 and d3.09) to C-4 (d164.20), C-5 (d110.32) and
C-6, and from H-3 (d6.32) to C-1 and C-5 were also ob-
served in the HMBC spectrum. From these correlations,
the connectivities from C-1 to C-10 (partial structure A in
Figure 1B) were clarified. The attachment of an oxygen
atom at C-4, C-6, and C-10 was also confirmed by their
13C chemical shifts.
1H-13C long-range correlations from exomethylene
(H-23, d4.90 and d5.07) to C-11 (d150.90) and C-12
(d24.87) were observed in the HMBC spectrum. There-
fore, the presence of C-23–C-11–C-12–C-13 was estab-
lished (partial structure B in Figure 1B).
The presence of a cyclohexanone structure (partial
structure C in Figure 1B) in moverastin A was clarified
using the 1H-13C long-range correlations from H-20
(d0.61) to C-14 (d43.48), C-15 and C-19, from H-22
(d0.93) to C-18 (d213.77), and from H-17 (d2.36) to C-18
in the HMBC spectrum.
The connectivities of partial structures A, B, and C
were established by the 1H-13C long-range correlations
from H-23 (partial structure B) to C-10 (partial structure
A), and from H-20 (partial structure C) to C-13 (partial
structure B). The presence of OH at C-4, C-6, and C-10
was determined by elimination. From all the results de-
scribed above, the planar structure of moverastin A
was determined as shown in Figure 1A. Moverastin A
is a member of the cylindrol family [26].
The structure of moverastin B was analyzed in the
same way, and the planar structure of moverastin B
was confirmed to be identical to that of moverastin A.
The assigned 1H and 13C chemical shifts of moverastin
B are listed in Table 1. A comparison of 13C chemical
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(A) Structure of moverastin.
(B) HMBC and DQF COSY correlations of moverastin.shifts between moverastin A and moverastin B was per-
formed, and jDdCj values are shown in Table 1. Consid-
ering this result, and the positions of chiral carbons in
moverastin A (C-10, C-14, C-15, and C-19), moverastin
B was strongly suggested to be the C-10 epimer of mov-
erastin A.
Confirmation of the Structure of Moverastin
by the Synthesis of a Mixture of Diastereomers
at the C-10 Secondary Allylic Alcohol
To confirm that moverastin is a mixture of the two
diastereomers at C-10 ([10R]-moverastin [1] and
[10S]-moverastin [2] in Figure 1A), we synthesized its
presumed structure as a diastereomeric mixture (Fig-
ure 2). Since the stereochemistries of the three asym-
metric centers on the cyclohexanone ring were specu-
lated to be the same as those of other well-known
compounds of the cylindrol family based on NMR simi-
larity, we chose ascochlorin (3) as the chiral starting ma-
terial for the left-hand moiety. The ketone of 3 was first
protected as a cyclic acetal, and trisubstituted olefinwas cleaved selectively by ozonolysis in the presence
of pyridine to afford an enone (5) via 4 in excellent yield.
Hydrogenation of another disubstituted olefin followed
by enol-triflation of the methyl ketone (6) by Comins’
method [27] gave 7 (64% yield), which is a key precursor
for the coupling to generate the secondary allylic alco-
hol. Another right-hand segment for the coupling was
prepared starting from known protected orcinol 8 [28].
Ortholithiation at the aromatic carbon between the two
MOMO groups and treatment with ally bromide gave 9
in 60% yield. A formyl group was then introduced by
treatment with n-BuLi and DMF to afford 10 in 54% yield,
and subsequent ozonolysis gave dialdehyde (11) in 74%
yield. Next, a coupling reaction between 7 and 11 was
carried out successfully using the Nozaki-Hiyama-Kishi
procedure [29, 30], and 12 was obtained in 62% yield
as an approximately 1:1 diastereomeric mixture at
C-10. In this reaction, nonconjugated aldehyde reacted
predominantly, and a coupling product with benzalde-
hyde was observed only in a trace amount. Finally,
acid hydrolysis of ethylene acetal and MOM groups
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The 13C NMR spectrum of the synthetic moverastin
showed complete accordance with natural moverastin,
including the split peaks, and this result unambiguously
showed that natural moverastin is a diastereomeric mix-
ture at C-10.
Table 1. 13C and 1H Data for Moverastin in CDCl3
dH dC
DjdCjPosition A B A B
1 112.85 112.85 —
2 142.65 142.65 —
3 6.32 (s) 6.32 (s) 111.98 111.98 —
4 164.20 164.20 —
5 110.32 110.23 0.09
6 164.06 164.09 0.03
6-OH 12.84 (s) 12.84 (s)
7 2.50 (s) 2.50 (s) 18.05 18.05 —
8 10.05 (s) 10.05 (s) 192.84 192.84 —
9 2.89
(dd 7.2, 16.0)
2.85
(dd 7.2, 16.0)
28.53 28.49 0.04
3.09
(dd 2.0, 16.0)
3.13
(dd 2.0, 16.0)
10 4.45
(dd 2.0, 7.2)
4.45
(dd 2.0, 7.2)
76.60 76.55 0.05
11 151.01 150.90 0.11
12 1.90–2.00 (m)a 1.90–2.00 (m)a 24.87 24.98 0.11
2.20–2.25 (m)a 2.20–2.25 (m)a
13 1.40–1.60
(2H, m)a
1.40–1.60
(2H, m)a
35.56 35.56 —
14 43.48 43.43 0.05
15 2.00–2.10 (m)a 2.00–2.10 (m)a 36.13 36.13 —
16 1.55–1.65 (m)a 1.55–1.65 (m)a 30.92 30.95 0.03
1.85–1.95 (m)a 1.85–1.95 (m)a
17 2.35–2.45 (2H)a 2.35–2.45 (2H)a 41.54 41.54 —
18 213.77 213.77 —
19 2.53 (q 7.2) 2.53 (q 7.2) 50.41 50.41 —
20 0.61 (s) 0.61 (s) 15.38 15.38 —
21 0.90 (d 6.8) 0.91 (d 6.8) 14.96 15.03 0.07
22 0.93 (d 7.2) 0.93 (d 7.2) 7.57 7.52 0.05
23 4.90 (s) 4.90 (s) 108.99 108.77 0.22
5.07 (s) 5.07 (s)
Chemical shifts in ppm from TMS as internal standard.
a Multiplets with countless peaks are represented by a range of the
chemical shift, indicating where the multiplet starts and ends.Preparation of (10S)-Moverastin
and (10R)-Moverastin and Determination
of the Absolute Configurations
We then prepared (10S)- and (10R)-isomers of moveras-
tin to clarify the relationship between bioactivity and ste-
reochemistry at C-10. Since it was found to be difficult to
separate both isomers directly, we applied a standard
method to the optical resolution of secondary alcohols
(Figure 3). The intermediate (12) in the synthesis of mov-
erastin was converted into the corresponding (S)-a-
methoxy-a-trifluoromethylphenylacetate (MTPA ester),
and the two isomers were separated by preparative
HPLC. Methanolysis of the MTPA ester of each isomer
([10S]- and [10R]-13) and subsequent acid hydrolysis
gave (10S)- and (10R)-moverastin in 61% and 69% yield,
respectively. It should be noted that the separation was
successful, and no contamination by another stereo-
isomer was observed in the NMR spectrum of either
isomer.
The absolute configurations of the synthetic and nat-
ural moverastins were determined as follows. First, (R)-
MTPA esters of the two separated stereoisomers of 12
were also prepared, and the stereochemistries at C-10
of the two diastereomers were determined by modified
Mosher’s method [31]. Signs of Dd values (d(S)-MTPA-
d(R)-MTPA, described at the bottom of Figure 3) of the pro-
tons on the right side of MTPAO groups clearly differed
from those on the left side, and the stereochemistry at C-
10 of each isomer was assigned as depicted in Figure 3.
Second, CD spectra of natural moverastin (diastereo-
meric mixture) and our synthetic (10S)- and (10R)-mov-
erastins were compared. All of them showed quite sim-
ilar curves, indicating negative Cotton effects at 290,
286, and 289 nm, respectively. This result suggests
that (1) the influence of the asymmetric center at C-10
on CD spectra is very small, (2) their negative Cotton ef-
fects depend mainly on the octant rule of the chiral cy-
clohexanone moiety, and (3) the absolute stereochemis-
tries on the cyclohexanone ring of natural moverastins
are the same as those of ascochlorin, which is the start-
ing material of our moverastin synthesis. Finally, by
comparing the 1H and 13C NMR spectra of each isomer,
moverastin A and moverastin B were identified to beFigure 2. Synthesis of Diastereomeric Mixture of Moverastin
Reagents and conditions: (a) TsOH, HO(CH2)2OH, toluene reflux (at 70ºC), quant; (b) O3, CH2Cl2-pyridine, then Me2S, 99%; (c) H2, Pd-C, EtOAc,
quant; (d) KHMDS, 5-chloro-2-[N,N-bis(trifluoromethanesulfonyl)amino]pyridine, THF, 278ºC, 64%; (e) n-BuLi, CH2=CHCH2Br, TMEDA, THF,
220ºCwroom temperature, 60%; (f) n-BuLi, DMF, TMEDA, ether, 220ºCwroom temperature, 54%; (g) O3, CH2Cl2, then Ph3P, 74%; (h)
CrCl2, NiCl2, DMF, room temperature, 62%; (i) concentrated HCl, THF, room temperature, 82%.
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reomers of Moverastin
Reagents and conditions: (a) (R)-MTPACl,
DMAP, CH2Cl2, room temperature, 81%,
then HPLC separation; (b) NaOMe, MeOH,
0ºC, then concentrated HCl, THF, 0ºC, 69%
for (10R)-moverastin (1), 61% for (10S)-mov-
erastin (2).(10R, 14S, 15R, 19R)-moverastin (1) and (10S, 14S, 15R,
19R)-moverastin (2), respectively.
Effect of Moverastins A and B on the Migration
of EC17 Cells
The inhibitory activities of moverastins A and B were as-
sayed with the wound healing assay, as previously de-
scribed [32]. As shown in Figure 4A, moverastin A par-
tially inhibited the migration of EC17 cells at 3 mg/ml,
and completely inhibited it at 10 mg/ml, as judged from
the residual area between the cells inwardly migrating
from the edges of the scratch. Moverastin B also in-
hibited the migration of EC17 cells with the same dose
range (Figure 4A). The inhibitory activities of moveras-
tins A and B were reassessed with a chemotaxicell
chamber (Figure 4B). In this assay, EC17 cells were cul-
tured in a double-chambered well, where they were al-
lowed to migrate, and penetrate the filter separating
the chambers, to enter the lower chamber. After 24 hr
of incubation, the number of cells attached to the lower
side of the filter was counted. The IC50 values for mover-
astins A and B in this assay were 6.7 and 6.9 mg/ml, re-
spectively (Figure 4B). Moverastins A and B did not
show any cytotoxicity or growth inhibition after 72 hr to-
ward EC17 cells, up to 10 mg/ml (data not shown).
Inhibition of FTase by Moverastins A and B In Vitro
Among cylindrol family compounds, cylindrol A and
LL-Z1272e were reported to be inhibitors of FTase [26].
Since moverastins A and B were determined to be cylin-
drol compounds, we examined whether they have an
inhibitory effect on FTase. For this assay, FTase was par-
tially purified from EC17 cells, and recombinant GST-H-
Ras and [3H]-farnesyl pyrophosphate were used as the
substrates. As shown in Figures 5A and 5B, moverastins
A and B inhibited FTase in a dose-dependent manner.
With our assay system, the IC50 values of moverastinsA and B were 6.8 and 7.5 mg/ml, respectively. Kinetic
analysis revealed that the inhibitory pattern on the Line-
weaver-Burk plot of moverastin A versus H-Ras was
typical of noncompetitive inhibition, in which each line
met together on the x axis, as shown in Figure 5C.
From the Dixon plot analysis, the Ki value of moverastin
A against FTase was found to be about 5.5 mg/ml, as
shown in Figure 5D. The inhibitory pattern of moverastin
B versus H-Ras was also noncompetitive (data not
shown). In contrast, moverastins A and B did not show
any inhibitory activity against GGTase up to 10 mg/ml,
as judged from the amount of [3H]-GGPP bound to
GST-Rho A (Figures 5A and 5B).
Moverastins A and B Inhibit Migration of EC17 Cells
by Inhibiting FTase
The findings that moverastins A and B inhibited the mi-
gration of EC17 cells, and were potential FTase inhibi-
tors, led us to investigate whether the inhibition of cell
migration is due to the suppression of H-Ras activation
caused by the inhibition of FTase. First, we examined
the expression of H-Ras in cultured EC17 cells. EC17 cells
displayed relatively high levels of H-Ras protein com-
pared with other human tumor cells (see Figure S1). The
biochemical fractionation experiments revealed that
H-Ras was much more prominent in the membrane frac-
tion in EC17 cells (Figure 6A). However, treatment of cells
with 10 mg/ml of moverastin A reduced the amount of
H-Ras in the membrane fraction, which led to an increase
in cytosolic H-Ras, indicating that moverastin A inhibited
the activation of H-Ras by inhibiting the membrane local-
ization through the inhibition of FTase in EC17 cells. The
same procedure was carried out to detect the localiza-
tion of N-Ras. However, the same concentration of mov-
erastin A failed to inhibit the membrane localization of
N-Ras (Figure 6A). Similar results were obtained when
moverastin B was used (data not shown). Because the
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Migration in EC17 Cells
(A) Wounding was introduced into confluent
cultures of EC17 cells, as described in Ex-
perimental Procedures. The cells were incu-
bated with various concentrations of mover-
astin A or moverastin B.
(B) EC17 cells were incubated with various
concentrations of moverastin A (a) or mover-
astin B (b) in the top chamber for 24 hr. Then,
the number of cells that migrated through
the filter to the lower surface was counted.
The results are the mean 6 SD of five differ-
ent fields.activation of H-Ras is reported to further activate the
PI3K/Akt pathway [17–19], we examined the effect of
moverastin A on the phosphorylation of Akt. Moverastin
A inhibited the level of phosphorylated Akt with the same
dose range that inhibited the migration of EC17 cells
(Figure 6B). In contrast, the same dose range of mover-
astin A did not affect the levels of phosphorylated Erk1/
2, regulated by K- or N-Ras through the Raf/MEK path-
way. Similar results were obtained when moverastin B
was used (data not shown). The involvement of these
pathways in the motility of EC17 cells was examined
with a known inhibitor for each pathway. A PI3K inhibitor,
LY294002, inhibited the migration of EC17 cells under
conditions in which LY294002 inhibited the phosphoryla-
tion of Akt (Figures 6C and 6D). However, U0126, an in-
hibitor of MEK, did not inhibit the migration of EC17 cells,
in spite of the disappearance of phosphorylated Erk1/2.
Discussion
In the course of screening for inhibitors of tumor cell mi-
gration, we obtained moverastin from the culture broth
of Aspergillus sp. F7720. Although our present studies
suggest that moverastin is a mixture of two diaste-
reomers at the C-10 secondary allylic alcohol, the struc-
ture of each diastereomer (moverastins A and B) was de-
termined in this mixture by spectroscopic analysis,because the separation of each diastereomer by HPLC
was unsuccessful. The possibility that natural moveras-
tin is a mixture of two diastereomers at C-10 was con-
firmed by chemical synthesis of moverastin as a diaste-
reomeric mixture and by analysis of its NMR data. The
preparation of each diastereomer by chemical synthesis
revealed that moverastin A is a (10R)-isomer, and mov-
erastin B is a (10S)-isomer, and they are members of
the cylindrol family. Although several cyclindrols and
their synthetic analogs have been reported, moverastins
A and B are unique in having an exomethylene moiety in
their structures (Figures 1A and 1B). Both moverastins
had similar inhibitory effects on cell migration (Figures
4A and 4B). Therefore, we concluded that the configura-
tion of C-10 had no effect on the inhibitory activity of
moverastins A and B toward cell migration.
We also demonstrated that moverastins A and B in-
hibited FTase (Figures 4 and 5A); the inhibitory effects
are specific to FTase, because they did not inhibit
GGTase. Moreover, moverastins A and B inhibited
FTase and cell migration with almost the same dose
range and with the same inhibitory profile (Figures 4
and 5A). In addition, inhibitory patterns of moverastins
A and B are noncompetitive with H-Ras (Figure 5C).
These results correlated with the previously reported
FTase inhibitory pattern of LL-Z1272e, another cylindrol
family compound, which was also reported to be
Inhibition of Cancer Cell Migration by Moverastins
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FTase In Vitro
(A) Partially purified enzymes from EC17
cells were incubated with [3H]-FPP plus re-
combinant GST-H-Ras for FTase assay or
[3H]-GGPP plus recombinant GST-Rho A
for GGTase assay in the presence or ab-
sence of moverastin A or moverastin B. The
reaction was terminated by the addition of
TCA. The radioactivity of the TCA-insoluble
fraction was measured. The results are the
mean 6 SD of four independent experi-
ments.
(B) Partially purified enzymes from EC17
cells were incubated with [3H]-FPP plus re-
combinant GST-H-Ras for FTase assay or
[3H]-GGPP plus recombinant GST-Rho A
for GGTase assay in the presence or ab-
sence of moverastin A. The reaction was ter-
minated by adding SDS sample buffer, and
the product solution was subjected to SDS-
PAGE and analyzed by autoradiography.
(C) Lineweaver-Burk plot of initial velocity
versus GST-H-Ras concentration. Moveras-
tin A concentrations are 0 (rhombus), 1
(square), 3 (triangle), and 10 (circle) mg/ml,
respectively.
(D) Dixon plot of initial velocity versus mov-
erastin A concentration. GST-H-Ras concen-
trations are 65 (rhombus), 217 (square), and
650 (triangle) mg/ml, respectively.noncompetitive with Ras-peptide (Ras-CVLS) [26]. Be-
cause moverastins A and B inhibited FTase with similar
potencies, the configuration of C-10 had no effect on the
inhibitory activity against FTase.
It had not yet been reported that FTase-inhibiting cy-
lindrols suppress protein farnesylation in a cultured cell
system. Therefore, we examined whether moverastins
A and B could inhibit protein farnesylation in EC17 cells.
Moverastins A and B inhibited the membrane localization
of H-Ras in EC17 cells, suggesting that they could inhibit
the farnesylation of H-Ras in the cultured cell (Figure 6A).
By contrast, they did not inhibit the membrane localiza-
tion of N-Ras (Figure 6A). The difference can be ex-
plained by the finding that FTase inhibitors SCH 44342
and SCH 56582 inhibit the prenylation of H-Ras, but not
of N-Ras [33]. In addition, while H-, K-, and N-Ras are
substrates for FTase in vitro, K- and N-Ras, but not
H-ras, are also substrates for GGTase [34]. Thus, K- and
N-Ras are geranylgeranylated by GGTase in cells when
FTase is inhibited. Therefore, it is likely that N-Ras is nor-
mally farnesylated in EC17 cells, however, it may be sub-jected to geranylgeranylation by GGTase in moverastin
A- or B-treated EC17 cells, thereby retaining the ability
to translocate to the membrane. Thus, our findings sug-
gest that moverastins A and B could inhibit FTase, but
not GGTase, in the cultured cell.
Among human tumor cells tested, EC17 cells showed
high migrative capacity (data not shown) and a high level
of farnesylated H-Ras protein. It has been reported that
motility in human breast epithelial cells was induced by
H-Ras, but not by N-Ras [35]. We similarly found that
overexpression of H-Ras in NIH3T3 cells induced migra-
tion (data not shown). Taken together, expression of ac-
tivated H-Ras at a high level seems to be responsible for
the migrative capacity of EC17 cells. Because the dose
of moverastins A and B required to inhibit the membrane
localization of H-Ras is consistent with that for the inhi-
bition of cell migration in EC17 cells, inhibition of the mi-
gration of EC17 cells by moverastin A or B was solely
due to the inhibition of H-Ras farnesylation.
Although H-, K-, and N-Ras share many common sig-
naling pathways leading to similar cellular responses,
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Translocation in EC17 Cells
(A) EC17 cells were incubated with moveras-
tin A for 24 hr. Proteins were extracted and
separated into cytosolic and membrane frac-
tions, and then H- or N-Ras were detected
by immunoblotting as described in Experi-
mental Procedures. Total cell lysate was im-
munoblotted with anti-H-Ras or anti-N-Ras
antibody.
(B) EC17 cells were incubated with 10 mg/ml
of moverastin A for the periods indicated.
H-Ras in cytosolic and membrane fractions
was detected by immunoblotting as de-
scribed in Experimental Procedures. Total
cell lysate was immunoblotted with anti-H-
Ras, anti-phospho-Akt, anti-Akt, anti-phos-
pho-Erk, or anti-Erk antibody. The data
shown are representative of three indepen-
dent experiments.
(C) EC17 cells were incubated with the indi-
cated concentrations of LY294002 or U0126
for 24 hr. Then, cells were collected, total
cell lysate was prepared, and equal amounts
of lysate were examined by Western blotting
using anti-phospho-Akt, anti-Akt, anti-phos-
pho-Erk, or anti-Erk antibody.
(D) EC17 cells were incubated with the indi-
cated concentrations of LY294002 or U0126
in the top chamber for 24 hr. The cells that
migrated through the filter to the lower sur-
face were counted. The results are the
mean 6 SD of five different fields.studies abroad clearly demonstrate unique roles for
these three Ras. Unique functions of the Ras family
members at the molecular level are supported by the
demonstration that there are differences in the signal
transduction pathways induced by Ras proteins. K-
and N-Ras preferentially regulate the Raf/MEK/Erk path-
way, and H-Ras mainly regulates the PI3K/Akt pathway
[36–38]. Our finding that moverastins A and B inhibited
the PI3K/Akt pathway, but not the Raf/MEK/Erk pathway
(Figure 6B), indicated that moverastins A and B inhibited
signal transduction downstream of H-Ras, selectively.
The contribution of the Raf/MEK/Erk pathway and
PI3K/Akt pathway to cell migration differs with the cell
line or stimulation. For example, the Raf/MEK/Erk path-
way is necessary in the induction of cell migration by
HGF in Madin-Darby canine kidney epithelial cells [17].
On the other hand, insulin-like growth factor 1-stimu-
lated melanoma cell migration required the PI3K/Akt
pathway, but not Raf/MEK/Erk pathway [39]. Because
the migration of EC17 cells was suppressed by an inhib-
itor of the PI3K/Akt pathway, but not by an inhibitor of
the Raf/MEK/Erk pathway (Figures 6C and 6D), it ap-
pears that the PI3K/Akt pathway dominantly regulates
migration in EC17 cells. Taken together, our findings
suggest that moverastins A and B inhibited the migra-
tion of EC17 cells by inhibiting the PI3K/Akt pathway
through suppression of H-Ras farnesylation.
Significance
Despite significant advances in understanding the
fundamental aspects of cancer, the development of
metastatic lesions remains the predominant cause ofdeath for most cancer patients. Cell migration is a cru-
cial event in the spread of cancer and, consequently,
the metastatic process. This prompted us to develop
inhibitors of tumor cell migration as antimetastatic
drugs. Because microbial products display diverse
structures and unique activities, we have screened
for inhibitors of tumor cell migration of microbial ori-
gin. As a result, we obtained a compound, moverastin,
which belongs to the cylindrol family, fromAspergillus
sp. F7720. Among the cylindrol family, moverastin is
unique in having an exomethylene moiety at position
C-11. However, an analysis by NMR spectroscopy
raised the possibility that moverastin is a mixture of
two diastereomers. This was proved by an analysis
of a synthesized mixture of the two diastereomers.
Each synthetic diastereomer (moverastin A and mov-
erastin B) inhibited cell migrationwith similar potency.
Furthermore, both diastereomers displayed similar in-
hibitory activities for FTase in vitro, indicating that the
configuration of C-10 did not affect the inhibitory activ-
ity for either cell migration or FTase. Our findings dem-
onstrate that moverastins A and B inhibited the migra-
tion of tumor cells by inhibiting farnesylation of H-Ras,
and subsequent H-Ras-dependent activation of the
PI3K/Akt pathway. In this study, we found an effect
of the cylindrol family on cultured tumor cells. The
combination of a chemical approach and a cell biolog-
ical approach enabled us to determine the structure of
moverastin and to examine the structure-activity rela-
tionship and the biological function of moverastins A
and B in vitro and in vivo. We are currently synthesiz-
ingmoverastin derivatives, the structures of which are
based on our findings on the structure-activity
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1345relationship, and the biological activities of the deriva-
tives are under investigation.
Experimental Procedures
Materials
LY294002 and U0126 were purchased from Sigma Chemical Co. (St.
Louis, MO). Polyclonal antibody against H-Ras and polyclonal anti-
body against N-Ras were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA). Phospho-Akt (Ser473) antibody, Akt antibody,
phospho-p44/42 MAP kinase Erk1/2 (Thr202/Tyr204) antibody, and
p44/42 MAP kinase Erk1/2 antibody were purchased from Cell Sig-
naling Technology, Inc. (Beverly, MA).
Cell Culture
Human tumor cells, including EC17 cells, were grown in RPMI 1640
medium containing 5% fetal bovine serum (FBS).
Synthesis of Moverastin
(6 0 0R,7 0 0R,8 0 0R)-3-Chloro-4,6-dihydroxy-2-methyl-5-[3 0-methyl-
5-(6 0 0,7 0 0,8 0 0-trimethyl-1 0 0,4 0 0-dioxaspiro[4.5]dec-7 0 0-yl)penta-
2 0,4 0-dienyl]benzaldehyde (4)
A mixture of ascochlorin (3, 0.013 g, 0.32 mmol), ethylene glycol (0.40
g, 6.4 mmol), and p-toluene sulfonic acid (6.0 mg, 0.032 mmol) in tol-
uene (8 ml) was heated and refluxed through a column of MS 4A un-
der slightly reduced pressure (bath temperature: 70ºC) for 3 hr. The
reaction mixture was poured into a saturated NaHCO3 solution and
extracted three times with ether. The combined ether solution was
washed with water and the saturated NaCl solution, dried with
Na2SO4, and concentrated in vacuo. Column chromatography
(SiO2) of the residue afforded 4 (0.17 g, quantity). See Supplemental
Data for further details.
(6 0R,7 0S,8 0R)-4-(6 0,7 0,8 0-Trimethyl-1 0,4 0-dioxaspiro[4.5]dec-7 0-
yl)-but-3-en-2-one (5)
Ozone was passed through a cooled and stirred solution of 4 (0.16 g,
0.35 mmol) in pyridine (0.75 ml) and CH2Cl2 (15 ml) at278ºC until the
mixture turned to yellowish green. After the removal of excess ozone
by N2 bubbling (15 min), Me2S (0.5 ml, 6.8 mmol) was added drop-
wise to the mixture, and the temperature was raised gradually to
room temperature. After stirring for 1 hr at room temperature, sol-
vent was evaporated off and the residue was chromatographed on
SiO2, to give 0.086 g (99%) of 5 as a pale yellow oil. See Supplemen-
tal Data for further details.
(6 0R,7 0S,8 0R)-4-(6 0,7 0,8 0-Trimethyl-1 0,4 0-dioxaspiro[4.5]dec-7 0-
yl)butan-2-one (6)
A mixture of 5 (0.080 g, 0.32 mmol) and 10% Pd-C (33 mg) in EtOAc (5
ml) was stirred vigorously under H2 at room temperature for 3 hr. Af-
ter dilution of the mixture with EtOAc and filtration through Celite, the
solvent was evaporated off, to give 0.084 g (quantity) of 6 as a color-
less oil. See Supplemental Data for further details.
Trifluoromethanesulfonic Acid (6 0 0R,7 0 0S,8 0 0R)-1-[2 0-(6 0 0,7 0 0,
8 0 0-trimethyl-1 0 0,4 0 0-dioxaspiro[4.5]dec-7 0 0-yl)ethyl]vinyl este (7)
To a cooled and stirred solution of 6 (0.059 g, 0.23 mmol) in dry THF
(5 ml) was added, drop-wise, a solution of KHMDS (0.5 M in toluene,
0.75 ml, 0.37 mmol) under Ar at 278ºC. After stirring for 15 min at
the same temperature, the resulting enolate was quenched by the
addition 5-chloro-2-(N,N-bis[trifluoromethanesulfonyl]amino)pyridine
(0.13 g, 0.35 mmol), and stirring was continued for 1 hr. A saturated
NaHCO3 solution was then added, and the resulting mixture was ex-
tracted three times with EtOAc. The combined organic phase was
washed with water and the saturated NaCl solution, dried
(Na2SO4), and concentrated in vacuo. The residue was chromato-
graphed on SiO2 to give 0.057 g (64%) of 7. See Supplemental
Data for further details.
2-Allyl-1,3-bis(methoxymethoxy)-5-methylbenzene (9)
To a solution of 8 (6.37 g, 0.03 mol) and TMEDA (9 ml, 0.06 mol) in dry
THF (100 ml) was added n-BuLi (1.56 M in n-hexane, 23 ml, 0.036
mol) at220ºC. After 1.5 hr, allyl bromide (5.2 ml, 0.06 mol) was added
to the mixture at 220ºC, and stirring was continued overnight at
room temperature. The solvent was evaporated off, and the residue
was diluted with ether and washed with water and a saturated NaCl
solution. Drying on Na2SO4 and evaporation gave a crude product,
which was purified by column chromatography (SiO2) to give 4.54 g(60%) of 9 as a colorless oil. See Supplemental Data for further
details.
3-Allyl-2,4-bis(methoxymethoxy)-6-methylbenzaldehyde (10)
To a solution of 9 (2.07 g, 8.2 mmol) and TMEDA (7.4 ml, 49 mmol) in
dry ether (200 ml) was added n-BuLi (1.56 M in n-hexane, 15.8 ml, 25
mmol) at220ºC. After 2 hr, DMF (1.0 ml, 60 mmol) was added to the
mixture at220ºC, and stirring was continued overnight at room tem-
perature. The reaction mixture was diluted with ether and washed
with water and a saturated NaCl solution. Drying on Na2SO4 and
evaporation gave a crude product, which was purified by column
chromatography (SiO2) to give 0.63 g of starting material (9) and
0.868 g (54% based on recovery) of 10 as a colorless oil, which crys-
tallized when placed in a refrigerator. See Supplemental Data for
further details.
2,4-Bis(methoxymethoxy)-6-methyl-3-
(2-oxoethyl)benzaldehyde (11)
Ozone was passed through a cooled (278ºC) and stirred solution of
10 (0.293 g, 10.4 mmol) in CH2Cl2 (30 ml) until the solution turned pale
blue. After the removal of excess ozone by N2 bubbling (10 min),
PhP3 (0.301 g, 12.5 mmol) was added to the mixture, and the temper-
ature was raised gradually to room temperature. The solvent was
then evaporated off and the residue was chromatographed on
SiO2 to give 0.218 g (74%) of 11 as a colorless oil. See Supplemental
Data for further details.
(6 0 0 0R,7 0 0 0S,8 0 0 0R)-3-{2 0-Hydroxy-3 0-[2 0 0-(6 0 0 0,7 0 0 0,8 0 0 0-trimethyl-
1 0 0 0,4 0 0 0-dioxaspiro[4.5]dec-7 0 0 0-yl)ethyl]but-3 0-enyl}-2,4-
bis(methoxymethoxy)-6-methylbenzaldehyde (12)
To a solution of CrCl2 (44.0 mg, 0.148 mmol) and NiCl2 (2.2 mg) in dry
DMF (5 ml) was added a solution of 7 (14.4 mg, 0.0373 mmol) and 11
(21.0 mg, 0.0746 mmol) in dry DMF (5 ml) at room temperature. After
1 hr, the reaction mixture was poured into water and extracted three
times with ether. The combined ether solution was washed with
water and a saturated NaHCO3 solution, dried (Na2SO4), and con-
centrated in vacuo. Purification of the crude product by column
chromatography (SiO2) gave 12 (12.0 mg, 62%) as a colorless oil.
See Supplemental Data for further details.
Moverastin
To a solution of 12 (18.1 mg, 0.0347 mmol) in THF (0.5 ml) was added
concentrated HCl (0.2 ml), and the resulting mixture was stirred at
room temperature for 30 min. After neutralization by the addition
of a saturated NaHCO3 solution, the mixture was extracted three
times with EtOAc and the combined organic phase was washed
with water and the saturated NaHCO3 solution, dried (Na2SO4),
and concentrated in vacuo. The residue was purified by column
chromatography (SiO2) to give 10.9 mg (82%) of moverastin as color-
less crystals.
The NMR data on our synthetic moverastin were identical with
those on natural moverastin.
Separation of 10-Epimers of Moverastin
(S)-MTPA Esters of 12 ([10R]- and [10S]-13). To a stirred solution of
12 (48.4 mg, 0.093 mmol) and DMAP (34 mg, 0.279 mmol) in dry
CH2Cl2 (5 ml) was added (R)-MTPACl (35 ml, 0.186 mmol) under Ar
at 0ºC. After 1 hr, the reaction was quenched by the addition of a sat-
urated NaHCO3 solution and the product was extracted three times
with ether. The combined ether solution was washed with water and
the saturated NaCl solution, dried (Na2SO4), and concentrated in
vacuo to afford a crude product. Purification by column chromatog-
raphy (SiO2) gave a diastereomeric mixture of 13 (54.0 mg, 81%). See
Supplemental Data for further details.
Two 10-epimers were separated by preparative HPLC (SiO2, sol-
vent system: hexane-EtOAc [6:1]) and 26 mg of (10R)-13 and 26 mg
of (10S)-13were obtained. See Supplemental Data for further details.
(R)-MTPA Esters of 12. In the same manner as described for the
preparation of (10R)- and (10S)-13, (R)-MTPA esters of moverastin
were obtained in 82% yield (10.9 mg) from 11 mg of 12, two isomers
of which were separated by preparative HPLC to afford (10S)-
and (10R)-isomers (5 mg each). See Supplemental Data for further
details.
(10R)-Moverastin (1). To a stirred and ice-cooled solution of
(10R)-13 (27 mg, 0.037 mmol) in MeOH (0.5 ml) was added NaOMe
(28% in MeOH, 0.5 ml). After 1 hr at the same temperature, the reac-
tion mixture was neutralized by the addition of 3 N HCl and extracted
three times with ether. The combined ether solution was washed
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lution, dried (Na2SO4), and concentrated in vacuo. The residue was
chromatographed (SiO2) to give a mixture of (10R)-12 and partially
deacetalized ketone. The mixture was deluted with THF (0.5 ml)
and treated with concentrated HCl (0.2 ml) and worked-up as de-
scribed for the preparation of (10RS)-moverastin, to give 10 mg
(69%) of (10R)-moverastin as colorless crystals after chromato-
graphic purification. See Supplemental Data for further details.
(10S)-Moverastin (2). In the same manner as described above, 8.9
mg (61%) of (10S)-moverastin was obtained from 27 mg of (10S)-13.
See Supplemental Data for further details.
Wound Healing Assay
A confluent monolayer of EC17 cells (7.53 104 cells/well in a 48 well
plate) was scratched with a white tip to create a cell-free zone in
each well, about 1 mm in width. The medium was replaced with me-
dium containing 1% FBS with or without of test sample. After 24 hr,
cells were observed under the microscope.
Transwell Migration Assay
The chemotactic migration of cells was assayed in a chemotaxicell
chamber (KURABO, Osaka, Japan) as previously reported, with
some modifications [40]. The cells (3 3 105) suspended in medium
containing 1% FBS were added to the upper compartment of the
chamber, and were incubated with conditioned medium in the lower
compartment for 24 hr. The filter was fixed with MeOH and stained
with hematoxylin. The number of cells that migrated through the fil-
ter to the various areas of the lower surface was counted under the
microscope.
Assay Methods for FTase and GGTase
To obtain FTase and GGTase, we used a modification of the method
described by Omura et al. [41]. EC17 cells were lysed and centri-
fuged, and the supernatant was submitted to fractionation by ammo-
nium sulfate. Thew30%–60%-saturated ammonium sulfate fraction
was used as FTase and GGTase. cDNA corresponding to c-Ha-Ras,
was isolated from EC17 cells using RT-PCR, and subcloned into
pGEX-2T (Amersham Pharmacia Biotech, Tokyo, Japan). c-Ha-Ras
protein was expressed in DH5acells as a GST-fusion protein, and pu-
rified on glutathione-agarose beads (Sigma Chemical Co.). Fusion
protein was used for the FTase assay as a substrate. Human Rho A
cDNA was kindly provided by Dr. S. Narumiya (Kyoto University).
The human Rho A cDNA was subcloned into pGEX-2T. Rho A protein
was expressed in DH5a cells as a GST-fusion protein, and purified on
glutathione-agarose beads. Fusion protein was used for the GGTase
assay as a substrate.
To measure FTase and GGTase activity, we used a modification of
the method described by Omura et al. [41]. The standard reaction
mixture contained the following components in a final volume of
60 ml: 10 mg of partially purified enzymes from the cytosol of EC17
cells, 10 mg of recombinant GST-H-Ras protein for the FTase assay
or 8 mg of recombinant GST-Rho A protein for the GGTase assay,
0.06 mM of [3H]-FPP (596 GBq/mmol, New England Nuclear) for the
FTase assay or 0.08 mM of [3H]-GGPP (1.48 TBq/mmol, Amersham
Bioscience) for the GGTase assay, 50 mM Tris-HCl (pH 7.5), 50 mM
ZnCl2, 4 mM MgCl2 and 4 mM DTT. The reaction was initiated by ad-
dition of enzyme and incubated for 1 hr at 37ºC. The reaction was
stopped by addition of 0.5 ml of 1% SDS in MeOH and 0.5 ml of
30% TCA. After vortexing, the tubes were left for 1 hr on ice. The mix-
ture was then filtered on a Whatman GF/C filter, washed with 5 ml of
6% TCA using a Skatron cell harvester. The dried filter was finally
placed in a liquid scintillation counter. A blank value was determined
in a parallel incubation with boiled enzymes and was subtracted be-
fore calculating percent inhibition.
Separation of Plasma Membrane and Cytosolic Fractions
Cells were harvested and resuspended in buffer A (20 mM Hepes-
KOH, pH 7.5, 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1mM EGTA,
and 1mM DTT) containing 250 mM sucrose and a mixture of prote-
ase inhibitors (1 mM phenylmethylsulfonyl fluoride [PMSF], 1%
aprotinin, 1 mM leupeptin, 1 mg/ml pepstatin A, and 1 mg/ml chymo-
statin). The cells were homogenized and unbroken cells were re-
moved by centrifuging the homogenates at 1000 3 g for 10 min at
4ºC. The supernatant was centrifuged at 100,000 3 g for 1 hr at4ºC to prepare the cytosolic fraction. Pellets were lysed in RIPA
buffer at 4ºC with sonication. The lysates were centrifuged at
100,0003 g for 15 min at 4ºC to give the plasma membrane fraction.
Western Blotting
The cells were lysed in RIPA buffer at 4ºC with sonication. The ly-
sates were centrifuged at 15,0003 g for 15 min, and the concentra-
tion of the protein in each lysate was determined with Coomassie
brilliant blue G-250. Loading buffer (42 mM Tris-HCl, 10% glycerol,
2.3% SDS, 5% 2-mercaptoethanol, and 0.002% bromophenol
blue) was then added to each lysate, which was subsequently boiled
for 3 min and then electrophoresed on an SDS polyacrylamide gel.
Proteins were transferred to Hybond-P membrane (Amersham Phar-
macia Biotech) and immunoblotted with anti-H-Ras, anti-N-Ras,
anti-phospho-Akt (Ser473), anti-Akt, anti-phospho-p44/42 MAP ki-
nase Erk1/2 (Thr202/Tyr204), or anti-p44/42 MAP kinase Erk1/2 an-
tibody. Detection was performed with enhanced chemilumines-
cence reagent (NEN Life Science Products, Boston, MA).
Supplemental Data
Supplemental Data including one figure are available at http://
www.chembiol.com/cgi/content/full/12/12/1337/DC1/.
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